Form 4: ResMed Director Jan De Witte Receives RSU Grant

ResMed Inc. director Jan De Witte was granted 1,073 Restricted Stock Units, increasing his beneficial ownership.

Summary

• Jan De Witte, a director of ResMed Inc. (RMD), acquired 1,073 shares of ResMed Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this grant was November 20, 2025.
• The acquisition price for these RSUs was $0, as they represent a compensation grant.
• Following this transaction, Jan De Witte's beneficial ownership in ResMed Inc. stands at 6,316 shares.
• The granted RSUs are scheduled to vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but not a significant market-moving event on its own. It reflects standard corporate governance and compensation practices.

Positives

• The grant of Restricted Stock Units aligns the director's financial interests with the long-term performance and shareholder value of ResMed Inc.
• An increase in beneficial ownership by a director can signal confidence in the company's future prospects and strategic direction.

Future Outlook

The Restricted Stock Units granted to Director Jan De Witte are scheduled to vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date, indicating a future commitment period for the director's equity and aligning his incentives with the company's long-term performance.

Industry Context

This RSU grant is a standard practice for compensating directors in publicly traded companies, particularly within the medical device and healthcare technology sector. Such equity awards are designed to align the director's long-term interests with company performance and shareholder returns, a common governance strategy across the industry.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a prevalent compensation mechanism across various industries, including healthcare technology, mirroring practices observed at peer companies such as Philips (PHG) or Stryker (SYK).
• The specified vesting schedule, contingent on a future date or the annual meeting, is typical for equity awards structured to retain key talent and foster long-term incentive alignment within corporate governance frameworks.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value, potentially fostering better governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this director compensation filing.

Next Steps

• The 1,073 Restricted Stock Units will vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice and does not provide new fundamental information to warrant a change in investment recommendation. It reinforces alignment of director interests with shareholders but is not a catalyst for significant price movement.

Keywords

ResMed, RMD, Form 4, SEC Filing, Restricted Stock Units, RSU, Director Compensation, Insider Ownership, Stock Grant, Beneficial Ownership